- Stocks
- Pharma & Healthcare
- Clinitech Labor
Clinitech Labor share price
NSE: CTLLABPharma & HealthcareDiagnostics & Research
Clinitech Labor at a glance
With a market capitalisation of ₹9 Cr, it ranks 3934th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.
Its return on equity was 4.5% in FY26. Promoters held 64.20% of the company as of 31 Mar 2026.
Key numbers
- Market cap
- ₹9 CrRank 3934 on NSE
- Price to book
- 0.86×FY26
- ROE
- 4.5%FY26
- ROCE
- 6.6%FY26
- Debt to equity
- 0.06FY26
- Net profit margin
- 4.4%FY26
- Book value / share
- ₹40.52FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Clinitech Labor financials
| Item | FY26 |
|---|---|
| Revenue | ₹9 Cr |
| Operating profit | ₹1 Cr |
| Net profit | ₹0 Cr |
| EPS (₹) | ₹2.00 |
| Cash from operations | −₹1 Cr |
| Total debt | ₹1 Cr |
| Shareholders' equity | ₹9 Cr |
Clinitech Labor shareholding pattern
| Holder | 31 Jul 2024 | 30 Sep 2024 | 31 Mar 2025 | 30 Sep 2025 | 31 Mar 2026 |
|---|---|---|---|---|---|
| Promoters | 61.58% | 61.58% | 61.58% | 62.42% | 64.20% |
| Foreign institutions | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% |
| Non-institutions | 38.11% | 38.11% | 38.11% | 37.27% | 35.48% |
Clinitech Labor vs peers
The listed Pharma & Healthcare companies nearest to Clinitech Labor by market capitalisation.
Ask anything about Clinitech Labor
Pivot answers on the live chart with evidence you can check, and tests strategies against CTLLAB's own history. Try: “Why has CTLLAB moved over the last three months?” · “Backtest a 50-day moving-average crossover on CTLLAB over five years” · “Compare CTLLAB with GLHRL on margins and valuation”
Frequently asked questions about Clinitech Labor
What is the market cap of Clinitech Labor?
Clinitech Labor's market capitalisation is ₹9 Cr (₹9 Cr) at the 22 Oct 2026 close, ranking 3934th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Clinitech Labor?
Return on equity was 4.5% in FY26 and return on capital employed was 6.6% in FY26 (consolidated figures).
Is Clinitech Labor a debt-free company?
No. Clinitech Labor's debt-to-equity ratio was 0.06 in FY26, with total debt of ₹1 Cr.
What is the shareholding pattern of Clinitech Labor?
As of 31 Mar 2026: promoters 64.20%, foreign institutions 0.32%, non-institutions 35.48%.
Who are Clinitech Labor's competitors?
The listed Pharma & Healthcare companies closest to Clinitech Labor by market cap are Global Longlife, Looks Health, Broach Lifecare, Genomic Valley, Trinity League and Adline Chem Lab.
Is Clinitech Labor a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Clinitech Labor's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on CTLLAB against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with C · all NSE stocks · this page as text